Category: Biotech

Biotech Financial Tombstone

Custom financial tombstone commemorating an offering by Artelo Biosciences, a San Diego-based biopharmaceutical firm.

(20AJH203)
1 Image

Faceted Crystal Deal Toy

Custom deal toy celebrating a follow-on public offering by Applied UV, a technology company employing narrow-range ultra violet light (UVC) to combat pathogens.

(20AJH232)
1 Image

Lucite Tombstone for Biotech Series A Funding

Lucite tombstone celebrating Series A funding for Trailhead Biosystems. The Cleveland-based biotechnology company is focused on the application of machine-enabled technology.

(21ADH001)
1 Image

Faceted Circle Lucite Tombstone

Lucite tombstone celebrating a private placement and concurrent global offering of shares by Calliditas Therapeutics. Joint bookrunners in the offering by the Swedish biotech firm were Citi, Jefferies, and Stifel.

(20ALJ348)
2 Images
Lucite deal toy celebrating a public offering of American Depositary Shares, and concurrent private placement, by Calliditas Therapeutics. The pharmaceutical firm is based in Stockholm, Sweden.

Gene Therapeutics Deal Toy

Crystal deal toy commemorating the acquisition of Philadelphia-based Spark Therapeutics. The acquiring firm, Swiss pharmaceutical firm Roche, is headquartered in Basel.

(9ALJ621)
1 Image

Crystal Deal Toy with Thor’s Hammer

Crystal deal toy, incorporating an interior, 3-D etching of Thor’s hammer, commemorating a private placement by pharmaceutical company Photocure ASA. Based in Oslo, Norway, Photocure specializes in photodynamic therapies that make use of light-activated drugs.

(20LJW163)
1 Image

Medicinal Cannabis Deal Toy

Crystal deal toy celebrating the initial public offering by pharmaceutical firm Rua Bioscience. The New Zealand-based company is licensed to produce cannabis-derived medicines.

(20ALJ334)
2 Images
Custom financial tombstone commemorating the ipo of New Zealand-based medicinal cannabis firm Rua Bioscience.

New Drug Application Custom Crystal

Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma’s migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial.

(20ALJ356)
2 Images
Crystal commemorative marking the submission to the Food and Drug Administration (FDA) of a New Drug Application (NDA). INP104 was developed for the acute treatment of migraine headaches.

Logo-Themed Pharma Deal Toy

Crystal deal toy commemorating a loan facility provided for Biohaven Pharmaceuticals, based in New Haven, Connecticut.

(20ALJ278)
1 Image